August 30, 2008
Home
About
Submit Press Release
PR Firms
Editors/Journalists
Search Archives
 
News Releases by Category  
News by Country  
News by MSA  
All News for Today  
Browse News by Day  
News by Trackbacks  
All Press Releases for August 15, 2007 Subscribe to this News Feed  
 

Mesothelioma Clinical Trial in New York City Tests Experimental Mesothelioma Treatment

Download this press release as an Adobe PDF document.

Researchers are testing Cisplatin, Pemetrexed, and Bevacizumab to see if the new drug combination is more effective against malignant mesothelioma

New York, NY (PRWEB) August 15, 2007 -- Researchers at Columbia Presbyterian Hospital are currently conducting a mesothelioma clinical trial in New York City to determine if a new, experimental mesothelioma treatment is effective and safe. Patients enrolled in this study will be administered three therapeutic drugs--Cisplatin, Pemetrexed, and Bevacizumab-which will be used together to see if this new drug combination constitutes a more effective form of mesothelioma treatment than other standard therapies.

To be eligible for this mesothelioma clinical trial in New York City, prospective patients must not have undergone prior chemotherapy for the treatment of mesothelioma or have been treated with any of the drugs under the consideration of this study. Patients must also be willing to take B12 vitamin and folic acid supplements to participate in this mesothelioma clinical trial. New York City is the home of top cancer institutions such as Columbia Presbyterian Hospital. To learn more about this hospital and its cancer treatments, please click on the following link: http://www.nyp.org/

To lean more about this clinical trial that tests this new experimental mesothelioma treatment of Cisplatin, Pemetrexed, and Bevacizumab, please click on the following link: www.centerwatch.com/patient/studies/stu92726.html

Malignant mesothelioma is a terminal form of cancer that arises primarily in the lining of the lungs and the abdomen; it is caused by the inhalation of asbestos. Generally speaking, mesothelioma takes at least fifteen years for symptoms to manifest themselves after a person's initial contact with asbestos. Even if a person is only exposed to asbestos for a short period of time, it is possible for them to develop mesothelioma in later life. Because asbestos fibers are microscopic, exposure can occur without an individual being aware of it.

Mesothelioma attorneys at Levy Phillips & Konigsberg, LLP, have prosecuted mesothelioma claims in New York City, and throughout New York and New Jersey, for more than twenty-five years. LPK has law offices in New York City and Lawrenceville, New Jersey and directly represents victims of asbestos-related diseases, including mesothelioma.

###

Trackback URL: http://www.prweb.com/pingpr.php/SGFsZi1Db3VwLVRoaXItSGFsZi1UaGlyLVplcm8=


See the original story at: http://www.prweb.com/releases/2007/08/prweb546853.htm
Other Releases by this Member
Email this story to a colleague
Printer Friendly Version
Bookmark with del.icio.us
Bookmark with Y!MyWeb
Submit to Digg
Jay Berkowitz
CEPAC
561-716-1334
Email us Here

There are no multimedia files attached to this release. If this is your release you may add images or other multimedia files through your login.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2007, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright